blood sampling: Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein
Study summary
We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions.
Our overarching hypothesis is that early detection of MGUS/SMM in a high- risk population, along with the comprehensive characterization of genomic/epigenomic and microenvironmental/immune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.
Eligibility
Sex
ALL
Min age
30 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Must meet criteria of the high-risk population as described with one of the below criteria
* ≥ 30 years AND
* first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.
OR
* Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer '
* Voluntary written informed consent must be given with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
Exclusion Criteria:
* • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.
* Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia
* Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test.
Primary outcome measure(s)
Prevalence and Incidence — Every individual will have a different duration throughout the study depending on their diagnosis. Prevalence and Incidence of Monoclonal gammopathy of undetermined signiificance (MGUS)/smoldering multiple myeloma (SMM) in a high-risk population of family history positive individuals
Trial sites (4)
Facility
City
Region
Status
Soroka
Beersheba
Israel
Recruiting
Rambam healthcare campus
Haifa
Israel
Recruiting
Rabin medical center
Petah Tikva
Israel
Recruiting
TASMC
Tel Aviv
Israel
Recruiting
More Tel-Aviv Sourasky Medical Center trials in Israel
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
